ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) saw a large decrease in short interest in September. As of September 29th, there was short interest totalling 3,707,842 shares, a decrease of 37.4% from the September 15th total of 5,924,174 shares. Based on an average daily volume of 610,983 shares, the short-interest ratio is currently 6.1 days. Approximately 5.1% of the company’s stock are short sold.
ContraVir Pharmaceuticals (NASDAQ:CTRV) opened at 0.7061 on Friday. ContraVir Pharmaceuticals has a 12 month low of $0.45 and a 12 month high of $2.65. The firm has a 50 day moving average price of $0.54 and a 200-day moving average price of $0.75. The firm’s market capitalization is $55.08 million.
Separately, Maxim Group reaffirmed a “buy” rating and issued a $4.00 target price on shares of ContraVir Pharmaceuticals in a research report on Thursday, August 24th.
A hedge fund recently raised its stake in ContraVir Pharmaceuticals stock. Vanguard Group Inc. grew its position in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 17.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,414,475 shares of the biopharmaceutical company’s stock after acquiring an additional 366,192 shares during the quarter. Vanguard Group Inc. owned 3.79% of ContraVir Pharmaceuticals worth $1,400,000 as of its most recent SEC filing. 9.97% of the stock is owned by institutional investors.
About ContraVir Pharmaceuticals
ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100.
Receive News & Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.